As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche
Executive Summary
The US FDA has granted priority review for Pfizer's talazoparib, which would be the fourth PARP inhibitor on the market, though only the second for breast cancer behind Lynparza. Pfizer has a long-term eye on a combination of talazoparib with its PD-L1 inhibitor Bavencio, Oncology CMO Rothenberg told Scrip at ASCO.
You may also be interested in...
Pfizer Expands In Breast Cancer With Talazoparib Approval
The PARP inhibitor, acquired with Medivation, will launch in a field where Pfizer already has commercial experience through its CDK4/6 inhibitor Ibrance.
Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Ascletis was the first with a new listing under new Hong Kong rules, but BeiGene also sold shares on the HKEX; the companies raised more than $1bn combined. Also, TherapeuticsMD sold stock in the US to commercialize Imvexxy, Curon raised the latest $150m VC mega-round, and NewLink cut jobs in R&D refocus.
AstraZeneca Looks To Deliver On Its Promises In Oncology
Global Head of Oncology Dave Fredrickson took over the commercial leadership role in October. Now he is overseeing several key growth drivers, including Imfinizi and Lynparza, while building out a new hematology franchise. Fredrickson talked with Scrip about AstraZeneca's oncology strategy at ASCO.